UroGen (URGN) CMO Mark Schoenberg Exercises RSUs, Sells 871 Shares

What Happened

• Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd. (URGN), had 1,667 restricted stock units (RSUs) convert/settle into ordinary shares on Sept 7, 2026 (reported as an exercise/conversion of a derivative, code M). Following the settlement, an open-market sale of 871 shares occurred on Sept 8, 2026 at $42.92 per share, generating $37,383 in proceeds. The filing also reports a related disposition of 1,667 derivative shares at $0 (reported in connection with the RSU settlement/withholding).

Key Details

• Transaction dates and prices:
  • 2026-09-07: Conversion/settlement of 1,667 RSUs into ordinary shares (derivative exercise/conversion, code M).
  • 2026-09-07: Disposition of 1,667 derivative shares at $0 (reported as related to the RSU settlement).
  • 2026-09-08: Open-market sale of 871 shares at $42.92 each for $37,383 (code S).
• Shares owned after the transaction: Not specified in the filing.
• Notable footnotes:
  • F1: Each RSU equals a contingent right to one ordinary share.
  • F2: Shares were sold to satisfy withholding tax obligations upon RSU settlement.
  • F3: These RSUs were part of a 5,000-share grant on Sept 7, 2023 that vests in three equal annual installments beginning Sept 7, 2024.
• Timeliness: Filing date is Sept 9, 2026 for transactions on Sept 7–8, 2026; the report appears timely (Form 4 is generally due within two business days).

Context

• This was not a cash purchase (not a bullish buy); it reflects RSU vesting and routine tax-withholding activity. The conversion/settlement (code M) represents RSUs becoming shares; the reported $0 disposition indicates shares withheld/treated in connection with the settlement, and the separate open-market sale of 871 shares generated cash to satisfy withholding taxes. These kinds of transactions are common after equity awards vest and do not, by themselves, indicate management sentiment about the stock.